



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



Renin angiotensin system blockade ameliorates lead nephropathy



Hwee-Yeong Ng^a, You-Lin Tain^b, Yueh-Ting Lee^a, Chung-Yao Hsu^c, Terry Ting-Yu Chiou^a,
Pei-Chen Huang^a, Chien-Te Lee^{a,*}

^a Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

^b Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

^c Department of Neurology, Kaohsiung Medical University Hospital, Taiwan

ARTICLE INFO

Article history:

Received 16 July 2013

Available online 26 July 2013

Keywords:

Lead

Renin-angiotensin system

Renal injury

ABSTRACT

Lead intoxication is usually insidious and may cause a variety of complications such as kidney damage and hypertension. The role of intrarenal renin-angiotensin system (RAS) in lead-induced nephropathy has not been investigated. Adult male Sprague-Dawley rats were fed with water containing 250 ppm of lead acetate (lead group) and deionized water (control group) for 4 weeks. Another two groups started to receive intraperitoneal captopril (50 mg/kg/d) or losartan (10 mg/kg/d) after 2 weeks of lead feeding and continued for another 2 weeks. Immunoblotting was used to analyze the protein amount of intrarenal RAS components and transforming growth factor-beta (TGF- β). Compared with control group, lead exposure resulted in increased proteinuria after 2-week treatment (4.2 ± 0.9 mg/100 g vs. 1.8 ± 0.8 mg/100 g, $p < 0.05$) and 4-week (5.2 ± 1.7 mg/100 g, $p < 0.05$). Serum creatinine level was increased (0.40 ± 0.2 vs. 0.3 ± 0.04 mg/dL, $p < 0.05$) and calculated glomerular filtration rate (GFR) was decreased (2.68 ± 1.03 vs. 3.37 ± 0.11 mL/min, $p < 0.05$). Intrarenal angiotensin converting enzyme (ACE), angiotensin II (ANG II), angiotensin II type 1 receptor (AT1R) and transforming growth factor-beta (TGF- β) were upregulated in lead group. Captopril and losartan administration reduced proteinuria significantly (3.0 ± 0.50 mg/100 g of captopril and 2.7 ± 0.4 mg/100 g of losartan group) and lowered systolic blood pressure when compared with lead group. Furthermore, serum creatinine levels and GFR were improved by RAS blockade. Captopril treatment significantly reduced protein abundance of ACE, ANG II, AT1R and TGF- β . Losartan treatment also decreased ANG II and TGF- β . We concluded that lead exposure elicited intrarenal RAS activation with associated proteinuria and impaired renal function. RAS blockade was effective in alleviating lead-associated kidney injury and lowering blood pressure.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Exposure to environmental and occupational nephrotoxics is one of the important causes of kidney injury. Among various heavy metals, lead is historically recognized as a representative etiology of chronic kidney disease. Lead-based paint is the major source of intoxication but lead can also be found in drinking water, food containers and herbal remedies. Entry of lead into body is mainly through respiratory and gastrointestinal tracts [1]. In adults, approximately 90% of lead is stored in the bone [2]. There is a slow release from the bone with an estimated half life for 20–30 years [3], indicating an extended and chronic deleterious effect of lead on health.

Even at low level of lead exposure results in tubulointerstitial injury of the kidney [4]. Direct injury of proximal tubular cells with

intranuclear inclusion formation has been described as the characteristic of lead nephropathy [5]. Increased oxidative stress was considered as the underlying mechanism of lead-induced kidney [6]. The role of renin angiotensin system (RAS) in lead-induced nephropathy and hypertension is still controversial. Most of the previous studies investigated plasma concentration [7,8] rather than intrarenal RAS which ultimately determines the kidney injury. Abnormal activation of RAS elicits inflammatory cascade and aggravates the process of injury [9].

In the present study, we aimed to investigate the effects of chronic lead exposure on the kidney in terms of proteinuria, renal function and intrarenal RAS. We also evaluated the effects of RAS blockade on lead-induced nephropathy.

2. Materials and methods

2.1. Animals

Adult male Sprague-Dawley rats weighting 180–200 g were used for this experiment. The animals were maintained under a

* Corresponding author. Address: Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 123, Ta-Pei Road, Niao-Sung District, Kaohsiung 833, Taiwan. Fax: +886 7 7322402.

E-mail address: chientel@gmail.com (C.-T. Lee).

constant 12 h photoperiod at temperatures between 21 and 23 °C. The animals were allowed free access to food and water. The food contained sodium (0.33%), calcium (1.0%), and magnesium (0.16%). The animals were divided into four groups: control group, lead, captopril and losartan group. The lead group was fed with drinking water containing 250 ppm of lead acetate ($n = 12$) for 4 weeks whereas the control group were given deionized water ($n = 12$). The other two groups were administrated with captopril (50 mg/kg/d, $n = 12$) or losartan (10 mg/kg/d, $n = 12$) after 2 weeks of lead-containing water feeding. RAS blockade treatment were then continued for another 2 weeks in along with lead exposure. Body weight was measured weekly until end of study. At the end of study, 24 h urine samples were collected from the animals using individualized metabolic cages. The rats were then sacrificed and blood samples were withdrawn from the inferior vena cava for biochemical analysis. Animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Kaohsiung Chang-Gung Memorial Hospital, and all animal procedures were performed according to the IACUC policy.

2.2. Biochemical assay and blood pressure measurement

Serum and urinary creatinine and uric acid levels were measured by using the SYNCHRON CX DELTA system [Beckman, Fullerton, CA, USA] according to manufacturer's operating protocol. Whole blood lead level was determined by Atomic Absorption Spectroscopy (GBC Scientific Equipment, Australia). Twenty-four hours urinary excretion of protein was presented as mg per 100 g of body weight. Urinary uric acid excretion was calculated as ratio of uric acid divided by creatinine (mg/mg). Blood pressure was measured by indirect tailcuff method (Visitech BP2000, Visitech Systems, Apex, NC, USA). Data of three consecutive measurements were recorded and then averaged for each animal.

2.3. Immunoblotting study

The protocol and procedure of immunoblotting study were described as in our previous study [10]. In brief, kidney cortical sections were frozen at -80°C and then homogenized at 4°C in protein lysis buffer solution, containing 20 mM Tris-HCl (pH 7.4), 0.1% sodium dodecyl sulfate, 5 mM ethylenediamine tetraacetate, 1% Triton X-100, and a protease inhibitor cocktail tablet (Roche, Penzberg, Germany). After centrifugation at 12,000g for 10 min at 4°C , the protein concentrations were determined using bicinchoninic acid protein assays. The protein samples were then run on 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis for angiotensin converting enzyme (ACE), angiotensin II (ANG II), angiotensin II type 1 receptor (AT1R) and TGF- β . They were then transferred to nitrocellulose membranes. β -Actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as the internal control in this study. After washing and blocking were completed, the membrane was incubated with primary antibody of the target molecule [ACE: 1:300; Santa Cruz Biotechnology, Santa Cruz, Calif., USA; ANG II: 1:1000; Phoenix, Pharmaceuticals, Belmont, Calif., USA; AT1R: 1:1000; Santa Cruz Biotechnology, Santa Cruz, Calif., USA; TGF- β : 1:200; Santa Cruz Biotechnology, Santa Cruz, Calif., USA. β -Actin: 1:3000; Sigma Chemical Co., St. Louis, Mo., USA; GAPDH: 1:10,000, Millipore Corporation, Billerica, MA., USA) for 16 h. Further washing in 5% blocking milk was performed and the membrane was incubated with secondary antibody for 3 min. The dilution and preparation of secondary antibodies included β -Actin (1:10,000), GAPDH (1:10,000), ACE (1:1000), AT1R (1:2000, peroxidase-conjugated AffiniPure goat anti-mouse IgG, all purchased from Jackson ImmunoResearch Laboratories Inc., West Grove Pa., USA) and ANG II (1:7000), TGF- β (1:8000, anti-rabbit IgG, horseradish peroxidase-linked antibody, all purchased

from Cell Signaling Technology, Inc., Danvers, Mass., USA). The abundance of studied protein was then quantified by densitometric analyses. The changes in protein abundance were presented as percentages of control animal values.

2.4. Data evaluation

The biochemical values are expressed as means \pm standard deviation (SD). Protein abundance is shown as means \pm standard error of mean (SEM). Comparison among different groups was performed by using one way ANOVA and then examined by LSD post hoc test. A p value < 0.05 is considered statistically significant.

3. Results

Table 1 presents the body weight, daily urine amount, whole blood lead level and biochemical data of four group animals at end of experiment. The body weight was comparable but urine amount was increased in all lead exposure groups ($p < 0.05$). In lead-treated rats, whole blood lead concentration was elevated significantly than that of control group ($p < 0.005$). Serum uric acid levels were similar of all groups but urinary excretion of uric acid was significantly reduced in all lead exposed groups, especially in lead group. A significant increase of serum creatinine was found in lead group (0.40 ± 0.17 vs. 0.27 ± 0.04 mg/dL, $p < 0.05$) and no significant difference was noted between the two RAS blockade treatment groups and control animals.

After feeding with lead for 4 weeks, systolic blood pressure was higher than control animals (132.7 ± 6.5 vs. 122.0 ± 9.2 mm Hg, $p < 0.05$, Fig. 1). In RAS blockade groups, blood pressure was significantly lower than the lead group and did not differ with control animals (captopril: 126.4 ± 6.5 mm Hg; losartan: 120.9 ± 6.6 mm Hg). Daily urinary protein excretion was increased significantly after lead exposure for 2- and 4 weeks (4.17 ± 0.87 mg/100 g and 5.19 ± 1.70 mg/100 g, Fig. 2A). For the calculated GFR, a decrease of 21% in the lead group was noted compared to control group (3.37 ± 0.11 vs. 2.68 ± 0.23 mL/min, $p < 0.05$, Fig. 2B). We found GFR was not affected in groups treated with RAS blockade when compared to control group (captopril: 4.24 ± 0.80 mL/min; losartan: 4.46 ± 0.94 mL/min, $p > 0.05$).

A 2-fold increase in the abundance of ACE was noted than that of control group in lead group (Fig. 3A, $p < 0.05$). In captopril treatment group, abundance of ACE was diminished significantly comparing with lead group (137.2 ± 10.2 vs. $235.4 \pm 28.2\%$ of control, $p < 0.05$). In losartan treatment group, there was no significant difference (283.6 ± 39.4 vs. $235.4 \pm 28.2\%$ of control, $p > 0.05$). Lead exposure was associated with a significant increase in ANG II ($178.8 \pm 7.6\%$ of control, $p < 0.05$). Administration of RAS blockade reduced ANG II abundance significantly comparing with lead group (captopril: $95.2 \pm 3.0\%$ of control; losartan: $129.4 \pm 10.8\%$ of control, both $p < 0.05$). Significant increase in AT1R was noted in lead group ($173.1 \pm 8.9\%$ of control, $p < 0.05$). Captopril treatment reduced AT1R ($67.1 \pm 12.3\%$ of control, $p < 0.05$) when compared with lead group. Losartan treatment did not affect the lead-treatment result ($149.7 \pm 19.7\%$, $p > 0.05$).

Lead treatment induced increased renal abundance of TGF- β ($145.3 \pm 7.6\%$ of control, $p < 0.05$). With addition of RAS blockade, the amount was reduced when compared with lead group (captopril: $76.7 \pm 10.5\%$ of control; losartan: $108.6 \pm 7.9\%$ of control vs. $145.3 \pm 7.6\%$ of control, both $p < 0.05$).

4. Discussion


Our study clearly demonstrated that subacute lead exposure was associated with increased blood pressure, diuresis, proteinuria and

Table 1

Body weight, urine amount and biochemical data of four groups animals.

	Control (n = 12)	Lead (n = 12)	Lead + captopril (n = 12)	Lead + losartan (n = 12)
Body weight (g)	409.1 ± 18.9	403.6 ± 29.2	418.6 ± 21.1	390.8 ± 34.4
Daily urine amount (mL)	14.6 ± 4.6	20.3 ± 4.7 ^a	23.8 ± 7.7 ^a	23.4 ± 8.0 ^a
Whole blood lead (ug/dL)	<1.0	14.8 ± 5.4 ^a	12.6 ± 5.3 ^a	13.4 ± 4.9 ^a
Serum Cr (mg/dL)	0.27 ± 0.04	0.40 ± 0.17 ^a	0.24 ± 0.14 ^b	0.20 ± 0.08 ^b
Uric acid (mg/dL)	0.96 ± 0.11	0.74 ± 0.26	0.75 ± 0.35	0.77 ± 0.24
Urine uric acid/Cr (mg/mg)	0.43 ± 0.7	0.25 ± 0.04 ^a	0.28 ± 0.06 ^{a,b}	0.34 ± 0.05 ^b

Cr: creatinine.


^a *p* < 0.05 vs. control group.^b *p* < 0.05 vs. lead group.**Fig. 1.** Systolic and diastolic blood pressure of the animals. **p* < 0.05 vs. control; #*p* < 0.05 vs. lead.

impaired renal function. Furthermore, intrarenal RAS components, including ACE, ANG II and AT1R, were activated. Inhibition of intrarenal RAS by RAS blockade improved these abnormal manifestations. This finding provided evidence that pharmacological blocking can offer therapeutic benefit in lead-induced kidney disease.

In the present study, blood level of lead was just above the suggested acceptable level of blood lead (10 µg/dL) in human [11]. However, it was lower than previous animal studies [4]. Although we did not evaluate systemic lead toxicity, the renal manifestations we observed illustrated lead-induced kidney damage. Our findings were in accordance with previous clinical investigation that subclinical adverse effects could be present in humans with blood lead level below 10 µg/dL [12].

The relationship between hypertension and lead exposure has been well recognized [1]. In experimental model, several mechanisms have been proposed for this association. Of note, activation

of RAS with enhanced ACE activity was found in both acute [13] and chronic lead exposure [14]. Increased sympathetic nerve activity and reduction of nitric oxide both have been reported [15,16]. Because kidney plays an important role in blood pressure regulation, activation of intrarenal RAS may contribute to the development of hypertension. In our experiment, significant increase in systolic blood pressure was noted in lead-treated animals and RAS blockades such as ACE inhibitor and AT1R antagonist we used lowered the blood pressure to a similar degree. The beneficial effect of RAS blockade may either through its systemic inhibitory effect or its renal modulating effect or by both mechanisms.

**Fig. 2.** Daily urinary protein excretion (A) and GFR (B) **p* < 0.05 vs. control; \$*p* < 0.05 vs. lead-2wk; #*p* < 0.05 vs. lead-4wk or lead.




Fig. 3. Effects of lead on protein abundance of intrarenal RAS components and TGF- β . Immunoblotting of intrarenal ACE (A), ANG II (B), AT1R (C) and TGF- β (D) in different groups. * $p < 0.05$ vs. control; # $p < 0.05$ vs. lead.

Both progressive increase in proteinuria and decrease in GFR are two markers of chronic kidney disease. It is generally accepted that abnormal activation of intrarenal RAS is one of the underlying mechanisms responsible for kidney injury. A variety of renal cells including renal epithelial cell, podocyte, mesangial cells as well as vasculature are involved during RAS-mediating renal injury [17]. Increased activity of ACE has been reported in lung, kidney,

heart and aorta during lead exposure [14]. Although we did not measure systemic activity of RAS, our results provided direct evidence for the first time that there is enhanced RAS activity in the kidney during lead exposure. The underlying mechanism responsible for lead-induced activation of RAS is not clear. Lead has been reported to increase oxidative stress [6] and oxidative stress can thus cause RAS activation [18]. Furthermore, lead affects urinary

uric acid excretion which leads to hyperuricemia [19]. Uric acid directly causes renal arteriopathy [20] and increases juxtaglomerular renin expression [21]. The RAS activation induced by lead might be different from other renal diseases at cellular aspect. Increased ANG II was found in the tubular epithelium in both high salt [22] and diabetic experiments [23]. However, in lead-induced nephropathy, ANG II was mainly detected in the infiltrated inflammatory cells in tubulointerstitial regions [24]. RAS blockades act on RAS at different levels to exert their inhibitory effect. In the present study, effects of captopril and losartan were similar in proteinuria reduction and renal function improvement. In captopril treatment group, ACE was markedly suppressed and both ANG II and AT1R were not increased. On the other hand, by inhibiting AT1R, compensatory increase in ACE and ANG II was found in losartan treatment group. This observation was supported by previous study, showing the corresponding changes of RAS components after treatment with different RAS blockades [25].

Pharmacological intervention to suppress RAS is associated with blood pressure lowering due to its systemic inhibition. A modest but significant decrease in systolic blood pressure was noted in RAS blockade treated groups. Although blood pressure-lowering effect is renoprotective, the significant improvement of proteinuria and GFR by RAS blockade observed in our study in a rather short period may at least represent its non-hemodynamic effect. It is also possible that improvement in kidney damage can simultaneously reduce blood pressure. Enhanced diuresis by lead has been reported in previous study [26]. Direct toxicity of lead to tubular epithelium with interference of water reabsorption may explain the underlying mechanism responsible for the defect in concentrating ability [27]. However, neither captopril nor losartan can reverse this impairment.

The mainstay of treatment of lead nephropathy is chelation therapy with a variety of agents, such as 2,3-dimercaprol and meso-2,3-dimercaptosuccinic acid [28]. However, most chelators have adverse effects and the recovery of each involved organs was unpredictable [28]. Other potential therapeutic agents include mycophenolate mofetil and antioxidant such as lipoic acid [24,29]. However, the result of their effect is still limited. In present study, we showed that RAS blockades improved lead nephropathy as they have been proven in other primary or secondary renal diseases. Besides, as lead also induces hypertension, these agents would have a more favorable effect.

In conclusion, our study showed that lead exposure caused intrarenal RAS activation associated with increased blood pressure, proteinuria and renal function impairment. RAS blockades such as captopril and losartan both were effective in alleviating lead-induced renal injury and lowering blood pressure.

Acknowledgment

This work was supported by a research grant from Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan (CMRPG891351).

References

- [1] L. Patrick, Lead toxicity, a review of the literature. Part 1: Exposure, evaluation, and treatment, *Altern. Med. Rev.* 11 (2006) 2–22.
- [2] A.T. Phillip, B. Gerson, Lead poisoning – Part I. Incidence, etiology, and toxicokinetics, *Clin. Lab. Med.* 14 (1994) 423–444.
- [3] L.E.Jr. Wittmers, A.C. Aufderheide, A.C. Aufderheide, J. Wallgren, G.Jr. Rapp, A. Alich, Lead in bone. IV. Distribution of lead in the human skeleton, *Arch. Environ. Health* 43 (1998) 381–391.
- [4] C. Roncal, W. Mu, S. Reungjui, K.M. Kim, G.N. Henderson, X. Ouyang, T. Nakagawa, R.J. Johnson, Lead, at low levels, accelerates arteriopathy and tubulointerstitial injury in chronic kidney disease, *Am. J. Physiol. Renal Physiol.* 293 (2007) F1391–F1396.
- [5] K.R. Mahaffey, S.G. Capar, B.C. Gladen, B.A. Fowler, Concurrent exposure to lead, cadmium, and arsenic, *J. Lab. Clin. Med.* 98 (1981) 463–481.
- [6] F. Farmand, A. Ehdai, C.K. Roberts, R.K. Sindhu, Lead-induced dysregulation of superoxide dismutase, catalase, glutathione peroxidase, and guanylate cyclase, *Environ. Res.* 98 (2005) 33–39.
- [7] J.A. Keiser, A.J. Vander, C.L. Germain, Clearance of renin in unanaesthetized rats: effects of chronic lead exposure, *Toxicol. Appl. Pharmacol.* 69 (1983) 127–137.
- [8] J.J. Gonzalez, E.E. Werk, K. Thrasher, R. Behar, C.B. Loadholt, Renin aldosterone system and potassium levels in chronic lead intoxication, *South. Med. J.* 72 (1979) 433–437.
- [9] R. Rüster, G. Wolf, Renin-angiotensin-aldosterone system and progression of renal disease, *J. Am. Soc. Nephrol.* 17 (2006) 2985–2991.
- [10] H.Y. Ng, H.C. Chen, Y.C. Tsai, Y.K. Yang, C.T. Lee, Activation of intrarenal renin-angiotensin system during metabolic acidosis, *Am. J. Nephrol.* 34 (2011) 55–63.
- [11] W.J. Rogan, J.H. Ware, Exposure to lead in children – how low is low enough?, *N. Engl. J. Med.* 348 (2003) 1515–1516.
- [12] R.L. Canfield, C.R.J. Henderson, D.A. Cory-Slechta, C. Cox, T.A. Jusko, B.P. Lanphear, Intellectual impairment in children with blood lead concentrations below 10 microgram per deciliter, *N. Engl. J. Med.* 348 (2003) 1517–1526.
- [13] M.R. Simões, R.F. Ribeiro Júnior, M.V. Vescovi, H.C. de Jesus, A.S. Padilha, I. Stefanon, D.V. Vassallo, M. Salas, M. Fioresi, Acute lead exposure increases arterial pressure: role of the renin-angiotensin system, *PLoS One* 6 (2011) e18730.
- [14] A.M. Sharifi, R. Darabi, N. Akbarloo, B. Larijani, A. Khoshbaten, Investigation of circulatory and tissue ACE activity during development of lead-induced hypertension, *Toxicol. Lett.* 2 (2004) 153:233–238.
- [15] D. Tsao, H. Chang, H. Yu, C. Ho, The change of beta adrenergic system in lead-induced hypertension, *Toxicol. Appl. Pharmacol.* 164 (2000) 127–133.
- [16] H.C. Gonick, Y. Ding, S.C. Bondy, Z. Ni, N.D. Vaziri, Lead-induced HTN: interplay of nitric oxide and reactive oxygen species, *Hypertension* 30 (1997) 1487–1492.
- [17] H.M. Siragy, R.M. Carey, Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease, *Am. J. Nephrol.* 31 (2010) 541–550.
- [18] C. Fanelli, R. Zatz, Linking oxidative stress, the renin-angiotensin system, and hypertension, *Hypertension* 57 (2011) 373–374.
- [19] J.L. Lin, D.T. Tan, H.H. Ho, C.C. Yu, Environmental lead exposure and urate excretion in the general population, *Am. J. Med.* 113 (2002) 563–568.
- [20] M. Mazzali, J. Kanellis, L. Han, L. Feng, Y.Y. Xia, Q. Chen, D.H. Kang, K.L. Gordon, S. Watanabe, T. Nakagawa, H.Y. Lan, R.J. Johnson, Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism, *Am. J. Physiol. Renal Physiol.* 282 (2002) F991–F997.
- [21] M. Mazzali, J. Hughes, Y.G. Kim, J.A. Jefferson, D.H. Kang, K.L. Gordon, H.Y. Lan, S. Kivlighn, R.J. Johnson, Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism, *Hypertension* 38 (2001) 1101–1106.
- [22] M.I. Rosón, S. Cavallero, S. Della Penna, G. Cao, S. Gorzalczy, M. Pandolfo, A. Kuprewicz, O. Canessa, J.E. Toblli, B.E. Fernández, Acute sodium overload produces renal tubulointerstitial inflammation in normal rats, *Kidney Int.* 70 (2006) 1439–1446.
- [23] S. Mezzano, A. Droguett, M.E. Burgos, L.G. Ardiles, C.A. Flores, C.A. Aros, I. Caorsi, C.P. Vio, M. Ruiz-Ortega, J. Egidio, Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy, *Kidney Int. Suppl.* 86 (2003) S64–S70.
- [24] Y. Bravo, Y. Quiroz, A. Ferrebuz, N.D. Vaziri, B. Rodríguez-Iturbe, Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension, *Am. J. Physiol. Renal Physiol.* 293 (2007) F616–F623.
- [25] C.M. Ferrario, Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control, *Life Sci.* 86 (2010) 289–299.
- [26] F. Missoun, M. Slimani, A. Aoues, Toxic effect of lead on kidney function in rat wistar, *Afr. J. Biochem. Res.* 4 (2010) 21–27.
- [27] M. Loghman-Adham, Renal effects of environmental and occupational lead exposure, *Environ. Health Perspect.* 105 (1997) 928–938.
- [28] S.J. Flora, V. Pachauri, Chelation in metal intoxication, *Int. J. Environ. Res. Public Health* 7 (2010) 2745–2788.
- [29] M. Pande, S.J. Flora, Lead induced oxidative damage and its response to combined administration of α -lipoic acid and succimers in rats, *Toxicology* 177 (2002) 187–196.